ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening

Health Technology Assessment

Volumn 13, Issue 51, 2009, Pages 1-126

  Kitchener, H C ^a   Almonte, M ^b   Gilham, C ^b   Dowie, R ^c   Stoykova, B ^c   Sargent, A ^a   Roberts, C ^a   Desai, M ^d   Peto, J ^b,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISTRESS SYNDROME; DYSKARYOSIS; ECONOMIC EVALUATION; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LABORATORY; LIQUID; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SCREENING; SEXUALITY; SOCIAL PSYCHOLOGY; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS EXAMINATION; VIRUS INFECTION; WART VIRUS;

ADULT; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATABASES AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRIMARY HEALTH CARE; QUESTIONNAIRES; STATE MEDICINE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 73249119973     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta13510     Document Type: Article

References (81)

1. Soutter W, de Barros Lopes A, Fletcher A, Monaghan J, Duncan I, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-80.
2. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93.
3. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318(7188):904-8.
4. Peto J, Gilham C, Fletcher O, Matthews F. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-56.
5. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132(10):810-19.
6. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19.
7. Clifford GM, Smith J, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-7.
8. Kjaer SK, van den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325(7364):572.
9. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.
10. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70
11. NICE Appraisal on Liquid Based Cytology; Advice to the service London: National Institute for Clinical Excellence; 2003.
12. Cuzick J, Clavel C, Petry K, Meijer C, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119(5):1095-101.
13. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93(4):293-9.
14. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97.
15. Bulkmans N, Berkhof J, Rozendaal F, van Kemenade F, Boeke A, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
16. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
17. Brown R, Breugelmans J, Theodoratou D, Bénard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22(4):663-70.
18. UK Cervical Cancer mortality statistics. URL: http://info. cancerresearchuk.org/cancerstats/types/cervix/?a=5441 (accessed 25 September 2009).
19. Mortality statistics. Cause. review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2005. London: Office for National Statistics; 2006.
20. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3(14).
21. Dolan P, Gudex C, Kind P, Williams A. The TTO method, results from a general population survey. Health Econ 1996;5:141-54.
22. Eddy D. The frequency of cervical cancer screening Comparison of a mathematical model with empirical data. Cancer 1987;60(5):1117-22.
23. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281(4):347-53.
24. Wardle J, Pernet A, Stephens D. Psychological consequences of positive results in cervical Cancer screening. Psychol Health 1995;10:185- 94.
25. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E. Psychological response to cervical screening. Prevent Med 1995;24(6):610.
26. Marteau T, Kidd J, Cuddeford L, Walker P. Reducing anxiety in women referred for colposcopy using an information booklet. Br J Health Psychol 1996;1:181-9.
27. Kitchener HC, Burns S, Nelson L, Myers AJ, Fletcher I, Desai M, et al. A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. BJOG 2004;111(1):63-70.
28. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004;328(7451):1293.
29. Waller J, McCaffery K, Nazroo J, Wardle J. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 2005;92:265-70.
30. Histopathology reporting in cervical screening. No. 10. Sheffield: NHSCSP; 1999.
31. Kitchener H, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:56-61.
32. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53.
33. Guidance on the use of liquid-based cytology for cervical screening - Technical Appraisal Guidance 69. London: National Institute for Clinical Excellence; 2003.
34. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using l1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36(10):3020-7.
35. Peyton C, Gravitt P, Hunt W, Hundley R, Zhao M, Apple R, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183(11):1554-64.
36. Cubie HA, Moore C, Waller M, Moss S. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. J Clin Virol 2005;33(4):287.
37. stataCorp. STATA. In. release 9.1 edn. College Station TX; 2005.
38. Microsoft. Microsoft Access 2000. In. 9.0 edn; 1999.
39. Curtis L, Netten A. Unit cost of health and social care 2006. Canterbury, Kent: Personal Social Services Research Unit, University of Kent at Canterbury; 2006.
40. Pay Circular (A for C) 1/2006. Pay and Conditions for NHS staff covered by the Agenda for Change agreement. URL: www.aop.org.uk/uploaded-files/pc-afc- 2006-01.pdf (accessed 28 September 2009).
41. Moss S, Gray A, Marteau T, Legood R, Henstock E, Maissi E. Evaluation of HPV/LBC Cervical Screening Pilot Studies: Summary of Report to the Department of Health (Revised October 2004). Sheffield: NHSCSP; 2004.
42. Cervical Screening Programme England 2006/07 [NS]: the Information Centre, National Statistics; 2007. URL: www.ic.nhs.uk/pubs/cervscreen0607 (accessed 29 October 2007).
43. Stoykova B, Kuzmanov G, Dowie R. Putting National Institute for Health and Clinical Excellence guidance into practice: a cost minimization model of a national roll-out of liquid based cytology in England. Int J Technol Assess Health Care 2008;24(4): 391-8.
44. Dowie R, Stoykova B, Crawford D, Desai M, Mather J, Morgan K, et al. Liquid-based cytology can improve efficiency of cervical smear readers: evidence from timing surveys in two NHS cytology laboratories. Cytopathology 2006;17(2):65-72.
45. Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9(1):43-50.
46. Arnesen T, Trommald M. Are QALYs based on time trade-off comparable? A systematic review of TTO methodologies. Health Econ 2005;14(1):39- 53.
47. Steering Group Report on the Feasibility of Introducing Liquid Based Cytology: Scottish Cervical Screening Programme; 2002. URL: www.sehd scot.nhs.uk/publications/ScreeningLiquidCytologyv2.pdf (accessed 28 September 2009).
48. Liquid Based Cytology - Pilot Project. Cardiff: Cervical Screening Wales; 2003.
49. Karnon J, Peters J, Chilcott J, Platt J, McGoogan E. Liquid-based cytology in cervical screening: an updated rapid and systematic review. Technology assessment report commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence. Sheffield: School of Health and Related Research, University of Sheffield; 2003.
50. Moss S, Gray A, Legood R, Henstock E. Evaluation of HPV/LBC: cervical screening pilot studies. First report to the Department of Health on evaluation of LBC. Sutton, Surrey: Cancer Screening Evaluation Unit, Institute of Cancer Research; 2003.
51. Modernising Pathology Services. London: Department of Health; 2004.
52. Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme. Sheffield: NHSCSP; 2004.
53. Eggington S, Hadwin R, Brennan A, Walker P. Modelling the impact of referral guideline changes for mild dyskaryosis on colposcopy services in England Sheffield: NHS CSP; 2006. Report No.: 24.
54. Goldberg D, Hillier V. A scaled version of the General Health Questionnaire. Psychol Med 1979;9:139-45.
55. Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G. the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
56. Garratt A, Torgerson D, Wyness J, Hall M, Reid D. Measuring sexual functioning in premenopausal women. J Obstet Gynaecol 1995;102:311-16.
57. Davison A, Hinkley D. Bootstrap methods and their application. Cambridge MA: Cambridge University Press; 1997.
58. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. J Obstet Gynecol 2008;111:167-77.
59. GDP Deflator Figures. 2007. URL: www hm-treasury.gov.uk/economic-data- and-tools/gdp-deflators/data-gdp-index.cfm.
60. Laboratory organisation. A guide for laboratories participating in the NHS Cervical Screening Programme. No. 14. Sheffield: NHSCSP; 2003.
61. Beerman H, van Dorst EB, Kuenen Boumeester V, Hogendoorn PC. Superior performance of liquid-based versus conventional cytology in a population-based cervical Cancer screening program, Gynecol Oncol 2009;112:572-6.
62. Kitchener H, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol 2009;10:672-82.
63. Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, et al., group. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol 2007;107(1):S230-2.
64. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362(9399):1871.
65. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
66. Paavonen J, Maud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV) - 16/18 AS04-adjuvanted vaccine against cervical infection and preCancer caused by oncogenic HPV types (PATRICIA): final analysis of a double blind, randomised study in young women. Lancet 2009;374:301-14.
67. Health Protection Agency: Annual Report and Accounts 2007. London: Health Protection Agency; 2007.
68. Franceschi S, Herrero R, Clifford G, Snijders P, Arslan A, Anh P, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
69. Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al., The Canadian Women's HIVSG, Franco E Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol 2006;44(6): 1998-2006.
70. Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006;44(10):3680-5.
71. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71(3):2463-72.
72. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366(9490): 991-8.
73. Manhart LE, Holmes KK, Koutsky LA, Wood TR, Kenney DL, Feng Q, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 2006;33(8):502-8.
74. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297(8):813-19.
75. Bulkmans NWJ, Bleaker MCG, Berkhoj J, Voorhorst FJ, Snijders PJF, Meijer CJLM. Prevalence of types 16 and 33 is increased in high risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 and worse. Int J Cancer 2005;117:177-81.
76. Department of Health. National schedule of reference costs 2005-6 for NHS Trusts. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884 (accessed 25 September 2009).
77. Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ 2006;332(7533):79-85.
78. Guidelines on failsafe actions for the follow-up of cervical cytology reports. Sheffield: NHS Cancer Screening Programmes.; 2004. Report No.: Publication number 21.
79. McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 2006;82(2):169-74.
80. Bulkmans NWJ, Bulk S, Ottevanger MS, Rozendaal L, Hallenberg SM, van Kemenade FJ, et al. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate J Clin Pathol 2006;59:1218-20.
81. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002;9:49-51.